Suero equino para tratar el COVID-19

Buenos Aires – Argentine scientists inform that there is an intention to export to other countries of the region the hyperhuman sugar of origin that is produced and that it is expected to distribute among patients of COVID-19 in the week concluded.

“We are in contact with various Latin American countries (…) and analyzing the possibility of producing the country, if there is any plant that will determine the capacity at this time”, says the director of the Inmunova laboratory, Linus Spatz, at a press conference with international media.

Spatz indicates that “there is a need in the region, which is manifest”, debuted the general increase in coronavirus contagions in recent weeks.

In this sense, make sure that there is “advancing with Mexico to work” in conjunction and leave this equino that mitigates the effects of COVID-19 hasta allí. Asimismo, confirms that he encounters “dealing with the authorities of Spain” to analyze the application of suer in Iberian countries.

Immunova integrates the project, from public-private articulation, together with the Argentine Biological Institute (BIOL) to the National Administration of Laboratories and Institutes of Health Dr. Carlos G. Malbrán, who led the way.

The production begins with 60,000 monthly vials, which, according to Spatz’s proposal, for “between 12,000 and 15,000 treatments”, each patient uses between five and six vials.

The director of Inmunova created that he could read to produce “100,000 vials per month”, in a context in which the vacancy began in small countries in Latin America, one of the Argentines, which were vaccinated with Sputnik-V dose.

The Argentine Minister of Science, Technology and Innovation, Roberto Salvarezza, stated that the conclusion of the agreement is the result of “collaborative work” between the public and private companies, which he calls “a great effort”.

“The suer will have a very important impact on the treatment of those who are in a moderate phase or worse,” added Salvarezza.

The super-original origino equino produced in Argentina completed its ultimate phase of clinical studies and “demonstration of efficacy and security” in serious cases of COVID-19, a communiqué issued by the governing body.

Neutralizing capacity

It is clear that it is intended to distribute throughout the country, “is an immunotherapy based on equine policing, which has the ability to neutralize the SARS-CoV-2 virus and prevent it from propagating”, and, in addition, “has the wind of what can produce fast and great scale ”.

The results of the clinical study, based on the National Administration of Medicines, Food and Technology (Anmat) approved on December 22, positive results in the mortality rate (45%), the decrease in the requires intensive therapy (24%), and the need for respirators is low (36%).

The study evaluated the safety and efficacy of the drug in 242 adult patients (18 to 79 years) with moderate severity and was caused by the infection of SARS-CoV-2, confirmation of PCR, within 10 days of the initiation of syndromes and that required hospitalization.

Inmunova’s Scientific Director and Superior Investigator of the National Council of Scientific and Technical Investigations of Argentina (Conicet), Fernando Goldbaum Anmat.

In addition, the “mayor impact” he has seen in his studies is “the reduction of symptoms” in the most severe patients of COVID-19, as well as being classified as an “important hallmark” and, for that matter, has been sent to a medical journal review for studying its publication.

Goldbaum explained that the suer function because of the equine police antiquos act as a blocker of the most adverse effects of the virus in patients who have been killed by their own immune response.

Therefore, it is avoided that the virus replicates and takes longer to generate anti-virus.

Agreed with Spatz and Goldbaum, colleagues in Brazil and India develop similar initiatives.